Ahmedabad-based Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India, aiming to make advanced cancer treatment accessible to all. This drug targets specific genetic mutations prevalent in certain types of cancers, offering a more tailored and effective treatment approach.
According to Globocan 2022 data, India sees nearly 2.75 lakh newly diagnosed cancer patients, with a significant portion suffering from breast, ovarian, prostate, and pancreatic cancers. Patients diagnosed as HRD positive or with BRCA mutations stand to benefit from IBYRA, a next-generation targeted therapy specifically designed for them.
